Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:eLife
Autors principals: Jones, Nick K, Rivett, Lucy, Seaman, Shaun, Samworth, Richard J, Warne, Ben, Workman, Chris, Ferris, Mark, Wright, Jo, Quinnell, Natalie, Shaw, Ashley, Goodfellow, Ian G, Lehner, Paul J, Howes, Rob, Wright, Giles, Matheson, Nicholas J, Weekes, Michael P
Format: Artigo
Idioma:Inglês
Publicat: eLife Sciences Publications, Ltd 2021
Matèries:
Epidemiology and Global Health
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8064747/
https://ncbi.nlm.nih.gov/pubmed/33830018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.68808
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars